Kolkata, New Delhi, INDIA. New York, USA.
Business Aajkal, New Delhi, 05 May 2025: Biocon Ltd announced that its subsidiary, Biocon Biologics Ltd, has secured multiple market access agreements in the United States for its biosimilar drug Yesintek (ustekinumab-kfce), a version of Stelara, which is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
The company stated in a regulatory filing that these agreements collectively provide coverage across over 100 million lives in the U.S., marking a significant commercial breakthrough for Yesintek. The achievement positions Biocon Biologics as a key player in the competitive biosimilars market, particularly in the high-value immunology segment.